

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/845,715 04/30/2001		George Jackowski	2132.030	3820
21917 7	590 06/16/2006		EXAMINER	
MCHALE & SLAVIN, P.A. 2855 PGA BLVD			SKIBINSKY, ANNA	
PALM BEACH GARDENS, FL 33410)	ART UNIT	PAPER NUMBER
	•		1631	

DATE MAILED: 06/16/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Office Action Comme	09/845,715	JACKOWSKI ET AL.			
Office Action Summary	Examiner	Art Unit			
	Anna Skibinsky	1631			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DY - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period value to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE.	the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on <u>30 M</u>	arch 2006.				
	action is non-final.	:			
3) Since this application is in condition for allowar	nce except for formal matters, pro	secution as to the merits is			
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	33 O.G. 213.			
Disposition of Claims		: :			
4)⊠ Claim(s) <u>1 and 36-43</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5)⊠ Claim(s) <u>1</u> is/are allowed.					
6)⊠ Claim(s) <u>36-43</u> is/are rejected.					
7) Claim(s) is/are objected to.		;			
8) Claim(s) are subject to restriction and/o	r election requirement.	:			
Application Papers		<u>:</u>			
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).			
11) ☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119		:			
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	i-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority document	s have been received.	÷			
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the prior	rity documents have been receive	ed in this National Stage			
application from the International Bureau	u (PCT Rule 17.2(a)).	·			
* See the attached detailed Office action for a list	of the certified copies not receive	d.			
		•			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate			
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P 6) Other:	atent Application (PTO-152)			

Art Unit: 1631

DETAILED ACTION

Amendment to the Claims

Amendment to claims 1, 36, 37, and 41-43 are acknowledged. Claims 1 and 36-43 are under examination.

Claim Rejections - 35 USC § 101

The rejection of claim1 as being directed to non-statutory subject matter in the Office Action filed January 3, 2006 is withdrawn.

Claim Rejections - 35 USC § 112, 2nd Paragraph

The rejection of claims 1 and 36 as being Vague and Indefinite in the Office Action filed January 3, 2006 is withdrawn.

Claim Rejections - 35 USC § 112, 1st Paragraph

- 1. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 2. Claims 36-43 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to

Art Unit: 1631

which it pertains, or with which it is most nearly connected, to make and/or use the invention.

3. In In re Wands (8 USPQ2d 1400 (CAFC 1988)) the CAFC considered the issue of enablement in molecular biology. The CAFC summarized eight factors to be considered in a determination of "undue experimentation." These factors include: (a) the quantity of experimentation necessary; (b) the amount of direction or guidance presented; (c) the presence or absence of working examples; (d) the nature of the invention; (e) the state of the prior art; (f) the relative skill of those in the art; (g) the predictability of the art; and (h) the breadth of the claims.

In considering the factors for the instant claims:

- a) In order to use the claimed invention one of skill in the art must identify a specific amino acid sequence from a mass spectrometry peak that relates only the mass to charge ratio. For the reasons discussed below, there would be an unpredictable amount of experimentation required to practice the claimed invention.
- b) The description does not provide detailed guidance as to how to confirm a specific amino acid sequence with a mass spectrometry peak that only provides mass to charge ration information.
- c) The description does not provide working examples of confirming a specific amino acid sequence from a mass spectrometry peak.
- d) The nature of the invention, of confirming a specific polypeptide sequence required knowledge of the specific ordering of amino acids in the sequence.

Art Unit: 1631

- e) The prior art shows that mass spectrometry can give information of the mass to charge ratio of polypeptide fragments, however, determining the exact sequence from a single mass spectrometry peak is not taught.
 - f) The skill of those in the art of polypeptide sequence characterization is high.
- g) The predictability of the relationship of connection of the location of a single mass spectrometry peak (i.e. the polypeptide mass) to the exact sequence that confirms a specific polypeptide is unknown in the prior art.
- h) The claims is broad in that it does not specify how an exact polypeptide sequence can be confirmed from only a single mass spectrometry peak.

The skilled practitioner would first turn to the instant description for guidance in using the claimed invention. However, the description lacks clear evidence that a specific sequence of amino acids in a particular order can be determined from a single mass spectrometry peak. As such, the skilled practitioner would turn to the prior art for such guidance, however the prior art does not discuss the determination of amino acid arrangements from one mass spectrometry peak. Finally, said practitioner would turn to trial and error experimentation to confirm the polypeptide sequence claimed. Such amounts to undue experimentation.

4. Claim 36(c) recites "confirming the presence of ... amino acid residues 2-12 of SEQ ID NO:1 in said sample by identifying a mass spectral profile having an ion peak at about 1348 daltons...". The mass spectrometry peak at 1348 (or about 1348) is used to confirm the presence of the specific polypeptide with the sequence disclosed and described on page 31, lines 13-16 of the specification. However, the use of the mass

Art Unit: 1631

spectrometry peak at "about 1348 daltons" for the confirming of said sequence is not enabled because a sequence with same amino acids but in a different order of arrangement would also be detected at 1348 daltons. Additionally a similar amino acid sequence with slight modifications could also potentially have a mass of "about 1348" daltons. Therefore, the identification of the peak does not confirm the presence of the claimed sequence in the sample.

Allowable Subject Matter

5. Claim 1 is allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anna Skibinsky whose telephone number is (571) 272-4373. The examiner can normally be reached on 8 am - 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (571) 272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1631

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Anna Skibinsky, PhD

ANDREW WANG

JPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600